~~<i id='BBA7311741'><strike id='BBA7311741'><tt id='BBA7311741'><pre id='BBA7311741'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：Wikipedia 2025-09-05 13:47:39 - browse：4

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The UK government moves asylum

entertainment

focus

leisure time

entertainment

leisure time

1:29FILE-ThiscombooffileimagesshowsFacebookCEOMarkZuckerberg,left,andTeslaandSpaceXCEOElonMusk.ElonM

WSS

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Eat, drink, but be wary — 4 foods that interact with medications

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Rock icon Freddie Mercury pre

explore

Wikipedia

entertainment

In Memoriam: Notable people who died in 2023

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

State Dept. review finds Biden bears some blame for Afghanistan failures

Illinois to ban advertising for guns allegedly marketed to kids and militants

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Moderna hits safety problems in bold bid to reinvent medicine

Walensky prepares to leave CDC — and Congress — behind

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Hepatitis C has a cure — but many Americans still lack access to it

Parkland mass shooting to be reenacted for lawsuit

focus

Calls for Trump's election interference trial to be televised part of long debate

Illinois to ban advertising for guns allegedly marketed to kids and militants

Climate activists disrupt London Pride march to protest corporate sponsorship

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Trump Jan. 6 attorney John Lauro is ex

leisure time

leisure time

entertainment

leisure time